The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab Injections-Reference-Cited by-同舟云学术

The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab Injections

Published:2014-05 Issue:5 Volume:121 Page:1092-1101
ISSN:0161-6420
Container-title:Ophthalmology
language:en
Short-container-title:Ophthalmology

Author:

Funder

UCL Institute of Ophthalmology, University College London

Novartis Pharmaceuticals UK Limited

Publisher

Elsevier BV

Subject

Ophthalmology

Reference27 articles.

1. Ranibizumab for neovascular age-related macular degeneration;Rosenfeld;N Engl J Med,2006

2. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;N Engl J Med,2006

3. National Institute for Health and Clinical Excellence. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. NICE technology appraisal guidance 155. Last modified May 2012. Available at: http://www.nice.org.uk/nicemedia/live/12057/41719/41719.pdf. Accessed August 7, 2013.

4. Ranibizumab and bevacizumab for neovascular age-related macular degeneration;CATT Research Group;N Engl J Med,2011

5. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results;Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group;Ophthalmology,2012

Cited by 263 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and risk factors of fellow-eyes wet conversion in unilateral neovascular age-related macular degeneration over 15-year follow-up;Graefe's Archive for Clinical and Experimental Ophthalmology;2024-08-23

2. Macular neovascularization;Survey of Ophthalmology;2024-08

3. Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration;British Journal of Ophthalmology;2024-07-20

4. Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial;The Lancet;2024-07

5. Safety and Tolerability of Suprachoroidal Axitinib, CLS-AX, for Neovascular AMD; Phase 1/2a Open-Label, Dose-Escalation Trial;Ophthalmology Science;2024-07